DUBLIN–(BUSINESS WIRE)–The “U.S. Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 – 2028” report has been added to ResearchAndMarkets.com’s offering.
The U.S. clinical trials market size is expected to reach USD 32.4 billion by 2028, registering a CAGR of 5.3% over the forecast period.
The shift towards personalized medicine, increasing R&D investments, and growing disease variation, as well as prevalence, are favoring the market growth. There has been a rise in the prevalence of diseases due to which, pharmaceutical companies are increasing their R&D expenditure to launch new therapeutics in the market. That has, in turn, increased the clinical trial value and complexity. Furthermore, the lower cost of clinical trials as a result of outsourcing services has strengthened clinical trial services in the U.S. As the number of people affected by the coronavirus has reached one million, the rapid spread of the virus around the globe is causing significant challenges to clinical trials and may forever change the way future trials are conducted.
The hospitals & clinics are less accessible, and it is unsafe and extremely difficult for patients enrolled in clinical trials to travel to sites. The current pandemic has placed a huge strain on the industry and is also likely to affect data analysis and interpretation. But that has also led to discoveries of conducting clinical trials effectively and efficiently. One such approach is to use Artificial Intelligence (AI) technology for clinical trials. Artificial intelligence uses software apps, data analytics, virtual monitoring, and online platforms to conduct every step of the clinical trial process, including patient recruitment, counseling, and consent. It helps in increasing precision and focuses on the efficiency of clinical trials. Thus, AI-generated technology has been gaining momentum as a healthcare offering, and the COVID-19 is adding more fuel to this initiative.
U.S. Clinical Trials Market Report Highlights
- The phase III segment accounted for the largest revenue share in 2020. However, the phase I segment is estimated to register the fastest CAGR from 2021 to 2028
- Patent expirations of blockbuster drugs and global financial crisis are factors expected to propel the market growth over the forecast period
- The interventional design segment accounted for the largest share in 2020 and will expand further at a steady CAGR retaining the leading position over the forecast period
- The oncology segment dominated the market in 2020 owing to the increasing number of cancer cases
- The cardiovascular segment is also expected to witness significant growth over the forecasted period
Market Driver Analysis
- Adoption of new technology in clinical research
- Shift towards personalized medicine
- Growing disease variation and prevalence
- Increasing collaboration in biomedical research
- Growth in CRO market
Market Restraint Analysis
- Pricing pressure
- Industry Challenges
-
Rising cost of clinical trial
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Clinical Trials Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage for COVID-19
3.3.1 Therapeutics in development: 271
3.3.2 Vaccines in development: 106
3.4 Fast track of clinical trials
3.4.1 FDA initiative- CTAP
3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
3.5 Solidarity clinical trial
3.5.1 Participation in solidarity trials
3.5.2 Solidarity clinical trial for vaccines
3.6 Virtual clinical trials
3.6.1 In-home clinical services:
3.7 COVID-19 pandemic impact on clinical trial activity
3.7.1 Disrupted clinical trials:
3.7.2 Obstacles in clinical trials:
3.8 Market Dynamics
3.9 U.S. Clinical Trials Market Analysis Tools
Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis
4.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
4.2 Phase I
4.3 Phase II
4.4 Phase III
4.5 Phase IV
Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis
5.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
5.2 Interventional Studies
5.3 Observational Studies
5.4 Expanded Access Studies
Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis
Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis
Chapter 8 Company Profiles
- IQVIA Holdings Inc.
- PAREXEL International Corporation
- Pharmaceutical Product Development (PPD)
- Charles River Laboratory
- ICON plc
- PRA Health Sciences
- Syneos Health Inc.
- SGS SA
- Wuxi AppTec
- Eli Lilly and Company
- Novo Nordisk A/S
- Pfizer Inc.
- Covance Inc.
-
Clinipace
For more information about this report visit https://www.researchandmarkets.com/r/9mk2gn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900